Description

Rapastinel is a novel antidepressant drug approved as an adjunctive therapy for the treatment of treatment-resistant

major depressive disorder. It is a centrally active, intravenously administered (non-orally active) amidated tetrapeptide

(Thr-Pro-Pro-Thr-NH2) that acts as a selective, weak partial agonist (mixed antagonist/agonist) of an allosteric site at

the glycine site of the NMDA receptor complex (Emax ≈ 25%).

The drug is a rapid-acting and long-lasting antidepressant as well as robust cognitive enhancer by virtue of its ability

to both inhibit and enhance NMDA receptor-mediated signal transduction.

Application&Function

GLYX-13 is a long lasting and rapid acting antidepressant. Investigational drug for the treatment of depressive disoder.

GLYX-13 trifluoroacetate has been used as an activator of NMDA ( N -methyl-D-aspartate) receptor.